Armata Pharmaceuticals CEO Dr. Deborah Birx to Present at Phage Futures Annual Meeting

Armata Pharmaceuticals announced that CEO Dr. Deborah Birx will present at the 5th Annual Phage Futures Annual Meeting. The event will be held on November 19th in Boston, MA. Armata is a clinical-stage biotechnology company focused on developing pathogen-specific bacteriophage therapeutics for antibiotic-resistant infections using its proprietary technology. The company is advancing a pipeline of natural and synthetic phage candidates for various pathogens.

Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotechnology company specializing in pathogen-specific bacteriophage therapeutics, recently announced significant developments, including new financing and leadership transitions [1]. One of the most notable changes is the appointment of renowned healthcare leader Dr. Deborah L. Birx as the new Chief Executive Officer (CEO), effective immediately [1].

Dr. Birx, who will also join Armata's Board of Directors, brings extensive experience to the company, having served as the Coordinator of the White House Coronavirus Task Force under President Donald Trump from February 2020 to January 2021 [2]. Before her tenure at the White House, Dr. Birx held various leadership positions at the Centers for Disease Control and Prevention (CDC), where she made significant contributions to HIV/AIDS research and policy development [2].

The company will utilize the new financing, totaling $25 million, to advance its pipeline of therapeutic phage candidates, including AP-PA02 and AP-SA02, which target infections caused by Pseudomonas aeruginosa and Staphylococcus aureus, respectively [1]. Additionally, Armata will use the funds to complete the build-out of its state-of-the-art cGMP (current good manufacturing practices) manufacturing facility [1]. This new facility will provide Armata with the necessary manufacturing capacity to pursue strategic partnering opportunities while concurrently executing late-stage clinical trials.

On November 19th, 2023, Dr. Birx will present at the 5th Annual Phage Futures Annual Meeting, which will be held in Boston, Massachusetts [3]. This event brings together researchers, clinicians, and industry professionals to discuss the latest advances and applications of bacteriophage therapy.

Armata's focus on developing innovative bacteriophage therapies for antibiotic-resistant and difficult-to-treat bacterial infections is more relevant than ever, given the growing global concern over antibiotic resistance [4]. With Dr. Birx's expertise and leadership, the company is poised to make significant strides in this field.

References:
[1] Armata Pharmaceuticals. (2023, July 11). Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage Therapeutics. Retrieved from https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-new-financing-and-leadership-transition-to-accelerate-novel-bacteriophage-therapeutics-301873937.html
[2] White House. (2020, February 28). Dr. Deborah Birx. Retrieved from https://www.whitehouse.gov/briefings-statements/dr-deborah-birx/
[3] Phage Futures. (2023). Annual Meeting 2023. Retrieved from https://www.phagefutures.org/annual-meeting
[4] World Health Organization. (2019, September 27). Antibacterial resistance. Retrieved from https://www.who.int/news-room/fact-sheets/detail/antibacterial-resistance